The latest update is out from Takeda Pharmaceutical Co ( (JP:4502) ).
Takeda Pharmaceutical Co. has announced an update on its share repurchase program, acquiring 4,513,800 shares of common stock at a cost of JPY 20,144,679,100 between March 1 and March 31, 2025. This acquisition is part of a broader plan approved by the Board of Directors to repurchase up to 28.5 million shares, with a total acquisition cost of up to JPY 100 billion, aimed at enhancing shareholder value and optimizing capital structure.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Company Limited is a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan. It focuses on creating better health and a brighter future through life-transforming treatments in areas such as gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Takeda operates in approximately 80 countries and regions, driven by a commitment to patients, people, and the planet.
YTD Price Performance: 19.74%
Average Trading Volume: 20,806
Technical Sentiment Signal: Sell
Current Market Cap: $47.27B
Learn more about 4502 stock on TipRanks’ Stock Analysis page.